Clinical impact of HIV-related lipodystrophy and metabolic abnormalities on cardiovascular disease

被引：31

作者：

Behrens, GMN ^{[1
]}

Meyer-Olson, D ^{[1
]}

Stoll, M ^{[1
]}

Schmidt, RE ^{[1
]}

机构：

[1] Hannover Med Sch, Dept Clin Immunol, D-3000 Hannover, Germany

来源：

AIDS | 2003年 / 17卷

关键词：

HIV; antiretroviral therapy; coronary heart disease; lipodystrophy;

D O I：

10.1097/00002030-200304001-00018

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Metabolic complications and altered fat distribution associated with HIV infection and antiretroviral therapy may lead to accelerated coronary artery disease (CAD). The high prevalence of multiple cardiovascular risk factors in a significant number of HIV patients is a cause for concern in both patients and physicians. Non-invasive strategies to measure subclinical CAD have been inconclusive. Long-term studies are underway to determine cardiac event rates, intervention strategies and consequences for the clinical management of HIV disease. In the present paper, we summarize the most prevalent risk factors in individuals with HIV infection receiving highly active antiretroviral therapy by focusing on the clinical implications of metabolic abnormalities and HIV-related lipodystrophy on CAD. (C) 2003 Lippincott Williams Wilkins.

引用

页码：S149 / S154

页数：6

共 45 条

[11] Gynecomastia without lipodystrophy syndrome in HIV-infected men treated with efavirenz [J].

Caso, JAA ;

Prieto, JD ;

Casas, E ;

Sanz, J .

AIDS, 2001, 15 (11) :1447-1448

[12] Indinavir and systemic hypertension [J].

Cattelan, AM ;

Trevenzoli, M ;

Sasset, L ;

Rinaldi, L ;

Balasso, V ;

Cadrobbi, P .

AIDS, 2001, 15 (06) :805-807

[13]

Christiansen M, 2001, DIABETES, V50, pA512

[14]

Dubé MP, 2000, CLIN INFECT DIS, V31, P1216

[15]

EGGER M, 2000, 40 INT C ANT AG CHEM

[16] Acceleration of confirmed coronary artery disease among HIV-infected patients on potent antiretroviral therapy [J].

Friedl, AC ;

Jost, CHA ;

Schalcher, C ;

Amann, FW ;

Flepp, M ;

Jenni, R ;

Linka, A ;

Weber, R .

AIDS, 2000, 14 (17) :2790-2792

[17] Plasma homocysteine as a risk factor for vascular disease - The European concerted action project [J].

Graham, IM ;

Daly, LE ;

Refsum, HM ;

Robinson, K ;

Brattstrom, LE ;

Ueland, PM ;

PalmaReis, RJ ;

Boers, GHJ ;

Sheahan, RG ;

Israelsson, B ;

Uiterwaal, CS ;

Meleady, R ;

McMaster, D ;

Verhoef, P ;

Witteman, J ;

Rubba, P ;

Bellet, H ;

Wautrecht, JC ;

deValk, HW ;

Luis, ACS ;

ParrotRoulaud, FM ;

Tan, KS ;

Higgins, I ;

Garcon, D ;

Medrano, MJ ;

Candito, M ;

Evans, AE ;

Andria, G .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (22) :1775-1781

[18] Increased PAI-1 and tPA antigen levels are reduced with metformin therapy in HIV-infected patients with fat redistribution and insulin resistance [J].

Hadigan, C ;

Meigs, JB ;

Rabe, J ;

D'Agostino, RB ;

Wilson, PWF ;

Lipinska, I ;

Tofler, GH ;

Grinspoon, S .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2001, 86 (02) :939-943

[19] HYPERINSULINEMIA, UPPER BODY ADIPOSITY, AND CARDIOVASCULAR RISK-FACTORS IN NON-DIABETICS [J].

HAFFNER, SM ;

FONG, D ;

HAZUDA, HP ;

PUGH, JA ;

PATTERSON, JK .

METABOLISM-CLINICAL AND EXPERIMENTAL, 1988, 37 (04) :338-345

[20] Severe premature coronary artery disease with protease inhibitors [J].

Henry, K ;

Melroe, H ;

Huebsch, J ;

Hermundson, J ;

Levine, C ;

Swensen, L ;

Daley, J .

LANCET, 1998, 351 (9112) :1328-1328

← 1 2 3 4 5 →